Subscribe

Advertisement

Acute Myeloid Leukemia Cancer Virus

RVU120: Novel Mediator Complex Inhibitor in MDS/AML

The phase 1 trial aimed to investigate the therapeutic potential of RVU120, a specific CDK8/19 inhibitor, in overcoming differentiation blocks in MDS and AML. Researchers noticed that inhibiting overexpressed mediator complex proteins with CDK8/19 inhibitor RVU120 effectively alleviates differentiation blocks in MDS/AML. Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemias (AML) exhibit hematopoietic differentiation […]...

Advertisement

Advertisement

Advertisement

SELECT ONCOLOGY JOURNAL ARTICLES

Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors

Disparities in Survival Outcomes Among Patients With Metastatic Melanoma in Texas: Implications for Policy and Interventions in the Era of Immune Checkpoint Inhibitors

Objectives: Disparities exist in the length and quality of survival from melanoma. This study evaluated, in a Texas cohort, patient factors associated with melanoma survival and examined if newer immune-oncologic agents extend survival compared with …

American Journal of Clinical Oncology

Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials

Safety and Efficacy of Trastuzumab Deruxtecan for Metastatic HER2+ and HER2-low Breast Cancer: An Updated Systematic Review and Meta-Analysis of Clinical Trials

Objectives: Trastuzumab deruxtecan (T-DXd) is a novel antibody-drug conjugate (ADC) promising in treating metastatic HER2+ and HER2-low breast cancer. This updated systematic review and meta-analysis, integrating data from the latest clinical trials, aimed to evaluate …

American Journal of Clinical Oncology